| Mitchell Fung, MD | |
|
7300 N Fresno St, Fresno, CA 93720-2941 | |
| (559) 448-4500 | |
| Not Available |
| Full Name | Mitchell Fung |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 35 Years |
| Location | 7300 N Fresno St, Fresno, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205986015 | NPI | - | NPPES |
| 00G713210 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | G71321 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital - Fresno | Fresno, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy have been awarded a five-year, $14.5 million grant from the National Institutes of Health to continue leading and expand their research on HIV treatment and care in five Central African nations.
Healthcare systems face enormous challenges over the coming years. The increasing demands of an aging population, the rising cost of treatments and medications, and budget shortfalls are all issues that will need to be addressed if Europeans are to continue to enjoy high standards of care. eHealth, enabled by information and communication technologies, offers Europe solutions that can help avoid healthcare crisis.
New research provides fascinating insight into mechanisms that underlie recovery after damage to a region of the brain important for memory and attention. The research, published by Cell Press in the November 4th issue of the journal Neuron, highlights the role of undamaged portions of the brain that can "take over" and support the recovery of function.
Inter Press Service News Agency examines the shortcomings of treatments for neglected tropical diseases - which, according to the Drugs for Neglected Diseases Initiative (DNDi), account "for 12 percent of the global disease burden," and 1.3 percent of the new drugs developed between 1975 to 2004.
Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus.
› Verified 7 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy have been awarded a five-year, $14.5 million grant from the National Institutes of Health to continue leading and expand their research on HIV treatment and care in five Central African nations.
Healthcare systems face enormous challenges over the coming years. The increasing demands of an aging population, the rising cost of treatments and medications, and budget shortfalls are all issues that will need to be addressed if Europeans are to continue to enjoy high standards of care. eHealth, enabled by information and communication technologies, offers Europe solutions that can help avoid healthcare crisis.
New research provides fascinating insight into mechanisms that underlie recovery after damage to a region of the brain important for memory and attention. The research, published by Cell Press in the November 4th issue of the journal Neuron, highlights the role of undamaged portions of the brain that can "take over" and support the recovery of function.
Inter Press Service News Agency examines the shortcomings of treatments for neglected tropical diseases - which, according to the Drugs for Neglected Diseases Initiative (DNDi), account "for 12 percent of the global disease burden," and 1.3 percent of the new drugs developed between 1975 to 2004.
Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mitchell Fung, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3466 Ph: (510) 625-6262 | Mitchell Fung, MD 7300 N Fresno St, Fresno, CA 93720-2941 Ph: (559) 448-4500 |
News Archive
Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy have been awarded a five-year, $14.5 million grant from the National Institutes of Health to continue leading and expand their research on HIV treatment and care in five Central African nations.
Healthcare systems face enormous challenges over the coming years. The increasing demands of an aging population, the rising cost of treatments and medications, and budget shortfalls are all issues that will need to be addressed if Europeans are to continue to enjoy high standards of care. eHealth, enabled by information and communication technologies, offers Europe solutions that can help avoid healthcare crisis.
New research provides fascinating insight into mechanisms that underlie recovery after damage to a region of the brain important for memory and attention. The research, published by Cell Press in the November 4th issue of the journal Neuron, highlights the role of undamaged portions of the brain that can "take over" and support the recovery of function.
Inter Press Service News Agency examines the shortcomings of treatments for neglected tropical diseases - which, according to the Drugs for Neglected Diseases Initiative (DNDi), account "for 12 percent of the global disease burden," and 1.3 percent of the new drugs developed between 1975 to 2004.
Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus.
› Verified 7 days ago
Maulik Shah, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 7300 N Fresno St, Fresno, CA 93720 Phone: 559-448-4555 | |
Rami Alrezk, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 155 N Fresno St, Fresno, CA 93701 Phone: 559-499-6479 | |
Dr. John R Nelson, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 7061 N Whitney, Suite 101, Fresno, CA 93720 Phone: 559-299-0224 Fax: 559-299-4201 | |
Dexter T Estrada, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 7130 N Millbrook Ave Ste 100, Fresno, CA 93720 Phone: 559-326-1222 Fax: 559-326-1230 | |
Dr. Sherry Lopez, D.O. Rheumatology Medicare: Medicare Enrolled Practice Location: 3209 W Shaw Ave, Suite 114, Fresno, CA 93711 Phone: 559-224-4977 Fax: 559-224-4980 | |
Maria Flordeliz Arambulo, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6484 Fax: 559-499-6501 | |
Shreela Mishra, Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 7085 N Chestnut Ave Ste 101, Fresno, CA 93720 Phone: 559-323-9236 Fax: 559-323-0294 |